Solving the Unsolvable: Could Quantum and Other Non-traditional Computing Hold the Key to Accelerating Drug Development? – Hosted by JLabs

Full-scale quantum computers could have the potential to revolutionize many industries, solving previously computationally impossible problems and uncovering unimaginable new possibilities.

So why wouldn’t we apply this tool to try and solve the worlds greatest healthcare problems? This promising, new technology could simulate larger, more complex molecules, and could simultaneously review multiple molecules, proteins, and chemicals – all of which is currently unachievable with a standard computer. Quantum simulations could also hold potential to be able to replace laboratory experiments, reduce the cost of research, and minimize the need for human and animal testing.

Quantum Computing (QC) could be game-changing for the healthcare industry, but there are always potential positives and negatives to any new technology. While QC could drastically accelerate research and development and could give scientists the ability to solve previously unsolvable problems, we must also educate ourselves on the potential risks around cybersecurity, ethics, errors, and more.

Agenda:

11:00 AM Opening Remarks

11:05 AM Overview of Quantum Computing

11:15 AM Quantum Computing Applications in Drug Discovery

11:25 AM Panel Discussion

12:00 PM Q&A

12:30 PM End of Broadcast

Speakers:

Peter Clark, PhD

Head, Computational Science & Engineering, Janssen BioTherapeutics

Peter leads a dynamic, interdisciplinary team of scientists focused on accelerating the research and development of protein based therapeutics through the design and implementation of disruptive computational approaches and platforms. Prior to joining Johnson & Johnson, Peter served as the Director of Bioinformatics at the University of Pennsylvania, Perelman School of Medicine, where he worked closely with academic and commercial collaborators on the design, optimization, and evaluation of various gene therapy platform technologies from early research and development through commercially partnered IND enabling clinical studies. Peter’s diverse expertise in computational science, engineering, clinical molecular genetics, computational biology, and translational research has led to the publication of over 30 peer-reviewed scientific publications as well as two book chapters, several issued patents and three biotechnology spin-off companies.

More speakers to be announced!